Ep.26 - The Latest Clinical Study on GLP 1 Receptor Agonists

About this video

Seeds dissects a recent preprint reporting that semaglutide slowed epigenetic aging markers in a randomized trial of people with HIV-associated lipodystrophy. He repeatedly stresses the paper is not yet peer-reviewed and directs most of his skepticism at epigenetic clocks themselves: methylation measured in peripheral blood may not reflect what is happening in target tissues, different clocks give different answers, results vary widely, and, he argues, nothing has validated that improving a clock score actually extends life. He situates the finding in mechanisms he already teaches, visceral fat driving chronic inflammation and GLP-1 drugs offsetting that cycle, and uses the episode to argue that clinicians should follow molecular pathways rather than buy into headline biomarkers, citing the history of hormone therapy in women as a cautionary tale.

Key takeaways

• Check peer-review status before treating a study’s framing as established
• Seeds argues epigenetic clock scores are unvalidated as proof of extended lifespan
• Blood-based methylation may not represent methylation in the tissues that matter
• Visceral fat’s inflammatory burden is the mechanistic backdrop for the result discussed
• Following mechanisms, rather than surrogate numbers, is Seeds’ stated guardrail against past medical reversals

Episode details: published June 30, 2026 · 81 views · 38:12 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: Ep.50 - A Revolutionary NAD+ Pen · Next: Ep.16 - NAD+ and its Importance To Overall Cellular Health →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)